Toujeo takes aim at Tresiba with real-world and head-to-head diabetes data

French pharma major Sanofi (Euronext: SAN) is taking aim at Novo Nordisk’s (NOV: N) Tresiba (insulin degludec) with two batches of data comparing its newest insulin glargine product Toujeo with Novo’s long-acting insulin option.

Toujeo, a more concentrated version of the company’s insulin workhorse Lantus (insulin glargine), was approved by the US FDA in February 2015.

Tresiba, a new kind of ultra-long acting insulin for type 1 or type 2 diabetes, was approved in the USA six months later.